ArticleFrontiers in cellular and infection microbiology2025
Characterization of carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Molecular Characterization and Clinical Outcomes ofChildren (Basel, Switzerland) · 2026Article
- Clinical characteristics and 28-day outcomes of sepsis associated with klebsiella pneumoniae carbapenemase-producing Enterobacterales: a single-center retrospective cohort study.BMC infectious diseases · 2026Article
- Prevalence, Virulence, and Pathogenic Mechanisms of Mastitis-AssociatedVeterinary sciences · 2026Review
- Epidemiology, Virulence Factors, and Antibacterial Resistance ofMedicina (Kaunas, Lithuania) · 2026Review
- Observational
- Regional surveillance of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Biological characterization, sequence type distribution and drug resistance profiling ofFrontiers in veterinary science · 2026Article
- Clinical and molecular characteristics, antibiotic susceptibility, risk factors and predictors of mortality in carbapenem-resistant klebsiella pneumoniae bloodstream infections in Southern Sichuan, China: a 5-year multicenter study.Frontiers in cellular and infection microbiology · 2026Article
- Exploring the Role of Berberine as a Molecular Disruptor in Antimicrobial Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Therapeutic efficacy of different sulperazon dosing regimens in carbapenem-resistant Klebsiella pneumoniae: a retrospective analysis of 209 cases.American journal of translational research · 2025Article
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
- Clinical and Genomic Characteristics of Carbapenem-ResistantInfection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant Methods: Ninety-four CRKP isolates from bloodstream infections at the First Affiliated Hospital of Zhejiang Chinese Medical University were characterized for carbapenemase genes, antibiotic susceptibility, and virulence determinants. Clinical data were analyzed to identify risk factors for CRKP infection, and the Results: Most of the isolates (71.3%) were from the intensive care unit (ICU) patients. The Conclusion: Our study reveals the multifaceted resistance and virulence profiles of CRKP in bloodstream infections and highlights the potential clinical value of berberine hydrochloride as an adjunctive therapeutic agent. These findings support further clinical investigations into incorporating traditional Chinese medicine to improve outcomes in patients with CRKP bloodstream infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.